DDX3X and inflammatory bowel disease: We have rationally designed and synthesized a small molecule inhibitor of DDX3, RK-33, and our data demonstrate that this drug has a high potential of being used as a systemic therapy for IBD as treating human colonic epithelial cells with RK-33 reduces the expression of MMPs, which are important in the development of chronic inflammation.